Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	David Oxnam (Chair of the Board of Trustees)	
	Sarah Curtis	
	Angela Polanco	(Appointed 13 June 2025)
	Laura Thomas	(Appointed 28 April 2026)
	Angelo Ercia	(Appointed 11 September 2025)
	Catherine Anderson	(Appointed 11 September 2025)
	Bushra Khawaja	(Appointed 11 September 2025)
	Natalie Agboeze	(Appointed 11 September 2025)
	Andy Donnelly	(Appointed 11 September 2025)
	Ngozi Ayanru	(Appointed 11 September 2025)
	Hollie Shears	(Appointed 11 September 2025)
Chief Executive	Ashley Ball-Gamble	
Charity number	1182637 (England and Wales) SC049948 (Scotland)	
Company number	CE016951	
Operating name	CCLG	
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB	
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT	
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ	

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

CONTENTS

	Page
Trustees' report	1 - 12
Independent auditor's report	13 - 15
Statement of financial activities	16
Balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19 - 33

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees of The Children's Cancer and Leukaemia Group, trading as CCLG: The Children & Young People's Cancer Association (CCLG), are pleased to present their annual report and financial statements for the year ended 31 December 2025.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of CCLG as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

Expert clinical work

CCLG is the UK and Ireland's professional association for all those involved in the treatment, care and research of children and young people (aged 0-25) with cancer. At the end of 2025, our membership stood at more than 1,800 members.

We bring together the experts in children and young people's cancer through our professional membership, creating a powerful national network driving progress. Together, we shape better treatment and care: developing guidelines, sharing expertise, offering advice, leading groundbreaking research, and creating essential resources and education for professionals.

Our collective expertise sets the standard, advising, influencing, and advocating for excellence locally, nationally, and globally.

We carry out a wide range of activities to support our professional members, including:

- **Special Interest Groups and Member Networks**: Our Special Interest Groups (SIGs) bring together networks of members around specific cancer types, professions or disciplines, and key aspects of treatment and care. Our SIGs develop treatment guidelines, produce good practice guidance and resources to help professionals develop in their careers, develop and run educational opportunities for professionals, create new research projects, undertake quality improvement initiatives, provide networks for sharing best practice and new ideas, and lots more, with the ultimate aim of ensuring the best possible treatment and care for all children and young people.
- **Clinical treatment guidelines**: We develop national clinical treatment guidelines ensuring safe, consistent and standardised care for children with cancer. Where possible, children with cancer are treated on clinical trials. However, the nature of research means that there will not always be open trials

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

for some childhood cancers and using treatment guidelines is vital for ensuring equality of access to what is regarded by national experts as the best possible treatment currently available. CCLG members regularly review guidance and recommendations to cover all of the major children's cancers, including leukaemia. Our guidelines are written by national experts in the field of each tumour type, usually by members of the relevant CCLG Special Interest Group. Guidance and recommendations draw on evidence from international research and treatment protocols, and the aim is to ensure guidance is consistent with the standard of care internationally.

- **Education and professional development**: CCLG develops expert resources to support children and young people's cancer professionals in their careers, as well as providing professional education through meetings, conferences and webinars. We support the next generation of professionals including through our Paediatric Oncology Trainees Group and Early Career Researcher Network.
- **Our member website**: is a vital hub for professionals, providing a wealth of resources and educational opportunities, complemented by our online member community, allowing networking and good practice sharing opportunities beyond group meetings and events.
- **Professional voice for children, teenagers and young adults**: We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

Information and guidance

We support children and young people with cancer and their families in a variety of different ways:

- We provide trusted information and guidance for children and young people with cancer, their families, and everyone supporting them. Our expertise helps them navigate the challenges of cancer and its impact, offering reassurance and clarity when it's needed most.
- Our free booklets and factsheets, along with videos and our website, are a comprehensive resource for children and young people facing cancer, along with their families. Written by experts, including those with lived experience of children and young people's cancer, our information is reviewed regularly and accredited to the PIF Tick certification, so users can be assured it is trustworthy, and produced using strict quality criteria.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- Our online community provides a 'safe space' for parents of children with cancer to come together and share experiences, ask for advice, and, uniquely, ask expert questions of our professional membership.
- Our website is a comprehensive resource of childhood cancer information, providing a wide range of up-to-date expert information, personal stories and more.

Research

The incredible progress in treating cancer in children and young people is built on decades of dedicated research and clinical trials. Over the last 40 years, this research has transformed survival rates, with more than 80% of children now being cured. CCLG has been at the heart of this progress, driving research and collaboration to improve outcomes.

But there is still more to do. Some cancers remain difficult to treat, and many existing treatments cause long-term and life-changing side effects. We need more research to improve survival rates, develop kinder treatments, and ensure the best possible quality of life for children and young people after cancer.

At CCLG, we fund and support research across the entire cancer pathway-from diagnosis and treatment to patient experience and survivorship. We make sure research meets the real needs of children and young people with cancer, their families, and those who care for them. In 2022, we identified the top 10 priorities for childhood cancer research, shaped by the voices of children, young people, parents, and professionals.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Collaboration is at the heart of what we do. We work with leading researchers and organisations to drive forward impactful studies, ensuring the best projects and brightest minds receive funding. We partner with other charities to maximise investment in research and use our expertise to support smaller charities in funding high-quality studies with real impact.

We lead the UK Children's and Teenage, Young Adult & Germ Cell Tumour Cancer Clinical Research Groups, part of the national UK3CR network, shaping and overseeing clinical research across the UK. Our Special Interest Groups bring together experts to share knowledge and plan future research.

We create opportunities for discovery. We organise and support scientific meetings, ensuring vital research is shared, discussed, and developed. We empower our professional membership to be actively involved in shaping research. Our Early Career Research Network and dedicated funding for nurses, allied health professionals, and early-career researchers ensure the next generation of childhood cancer experts can continue to push boundaries and drive progress.

Our research strategy sets out our vision for the future of children and young people's cancer research - because every child deserves the best possible chance.
We work to share information about research, including results and outcomes, with the public, including through our popular research blog and a series of webinars on a variety of research topics.

Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

Policy and advocacy

We use our expertise and influence to make things better. By campaigning and advocating for children and young people with cancer, their families, and the professionals who support them, we're driving change where it matters most.

Working alongside politicians, governments, the NHS, and other organisations, we're pushing for progress and shaping a brighter future for young lives.

We combine our professional membership's expertise along with the voice of lived experience to develop position statements and policy ideas, shape campaigns, and respond to consultations from governments, the NHS, and other bodies about plans, policies, research or services for children and young people with cancer.

We also work in partnership with other organisations to ensure that children and young people's cancer has a strong, unified voice. We are a founding member of the Children and Young People's Cancer Coalition, and our Chief Executive is the current Chair. We also contribute to wider policy work where it affects children and young people with cancer, including through our membership of Cancer 52 (the alliance for rare and less common cancers), the Association of Medical Research Charities, the Wales Cancer Alliance, and the One Cancer Voice coalition.

Our Chief Executive was invited to be part of the Government's Children and Young People's Cancer Taskforce, working with the Department of Health and Social Care to drive forward improvements in the treatment and care of children, teenagers and young adults with cancer, to develop recommendations for children and young people's cancer as part of the government's National Cancer Plan, published in early 2026.

Early diagnosis

Early diagnosis saves lives. Spotting cancer in children and young people early means better outcomes, fewer long-term effects, and the best chance of survival. That's why we're dedicated to making sure children and young people with symptoms of cancer get a diagnosis as quickly as possible.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

We raise awareness of the signs and symptoms, empowering families and communities to act sooner. For healthcare professionals, we provide tools and resources to support informed decisions about tests and scans. Together, we're working to ensure every child and young person gets the timely diagnosis they need.

We have information about the signs and symptoms of cancer in children and young people, and information and resources for healthcare professionals about diagnosing cancer in children and young people.

During the year we continued to focus on research to generate a new evidence base on how cancer presents in children and young people, as well as the routes to diagnosis, to inform a new national campaign, Child Cancer Smart, which launched during the year. Child Cancer Smart aims to raise awareness of the signs and symptoms of children's cancer and provide tools for GPs and other healthcare professionals to support them to make timely and accurate referrals.

We measure our success in achieving our objectives in a number of ways:

- Analytics around our health information provision, including the number of information products distributed, website and social media analytics, and user-provided feedback, are used to measure our work in supporting patients and their families.
- The number of members and retention of members, attendance at and written feedback from education days, meetings and conferences, and informal member feedback, are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals, and the number of projects that led to further funding from ourselves or another research funder.
- We have now begun developing our new strategic plan, set to launch in 2026. As part of this work, we will consider how we better measure and report on our impact.

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors must contend with life-long and life-limiting side effects. Highlights of our achievements during the year are set out under each of the strategic goals defined in our organisational strategy.

During the year, Children's Cancer and Leukaemia Group and Teenagers and Young Adults with Cancer (TYAC) merged their memberships to form a new professional association which brings together healthcare professionals and researchers to achieve the best possible care and support for children, teenagers and young adults with cancer. TYAC had formerly merged with CCLG in 2019, but by bringing the two memberships fully together, recognising the overlap between them, this approach will enhance our membership offer, especially to those who work across the patient age groups, and strengthen the work we do across research, health information, and early diagnosis.

At the same time, we re-branded the organisation to become 'CCLG: The Children & Young People's Cancer Association'. This new name, along with a new website, fresh branding and a change to the way we talk about our work, will further raise our profile and grow fundraising income to support our work.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. Highlights for 2025 include:

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

- The CCLG Annual Conference continues to be the key professional event in children and young people's cancer. Held at the International Convention Centre, Birmingham, in March, the conference welcome more than 700 delegates featuring special interest sessions for specific membership groups, engaging presentations from key leaders in cancer research, treatment and care, in-depth multidisciplinary and clinical insights sessions and more, providing a unique opportunity for learning, networking, and sharing news and discoveries across the UK and Ireland children and young people's cancer professional community.
- The CCLG Annual Conference also featured the return of the CCLG Member and Research Awards, recognising the contributions of individuals and teams to the work of CCLG and children and young people with cancer. Nominated by their fellow CCLG members, the 13 Member Award winners were chosen based on key criteria. These included measuring the impact and tangible benefits of their work, and whether they have demonstrated CCLG values, such as professionalism, compassion and commitment, as well as criteria specific to the individual award itself. The seven Research Awards recognised outstanding contributions to research in children and young people's cancer, with the winners presenting their work during the conference.
- We ran a full programme of professional meetings and education events during the year, virtually and in-person. Our professional meetings bring together our Special Interest Groups to consider research, education, guidelines and future plans for specific professional groups within our membership, or specific cancer types. Educational events provide vital learning opportunities which ultimately improve the treatment and care of children and young people with cancer.
- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high-quality and evidence-based treatment for all children and young people, particularly in diseases where there are currently no open clinical trials. Our new 'guideline fellowships' provided national leadership opportunities to two of our professional members, supporting their professional development in addition to enhancing the work of our guidelines programme, implementing a high-quality, robust approach to guideline production and increasing the support available to our members working on guidelines.
- Our online member community, CCLG Connect, continued to go from strength to strength, providing a space for members to connect with each other, participate in group activities, share best practice and research outputs, ask questions and disseminate useful resources.
- Our Chief Nurses, funded as part of our strategic partnership with Young Lives vs Cancer, continued to enhance support for nursing and allied health professional members of CCLG, developing resources and supporting professional networks, as well as providing clinical and health system insight and intelligence to Young Lives vs Cancer to support their services and policy work. We also provided two secondment roles to nursing members during the year, working with the CCLG Chief Nurses to undertake specific projects reviewing CCLG resources widely used across NHS services in the UK. These secondments also provide professional development and national leadership opportunities for nursing members of CCLG.
- Along with Young Lives vs Cancer, The Ellen Macarthur Cancer Trust, Shine Cancer Support and Alike, we continued our partnership work as part of the North Star Cancer Collective. This work aims to build on the findings of previous research, focusing on system change to see our collective 'North Star Vision' come to fruition. During the year, we were pleased to be invited to present some of the work of the North Star Cancer Collective at the International Society of Paediatric Oncology's annual global congress in Amsterdam.
- We continued to support a number of National Advisory Panels, groups of national experts in particular childhood cancers, to provide expert advice and treatment guidance for difficult-to-treat cases across the UK.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals.

Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2025:

- The results of the landmark Childhood Cancer Diagnosis Study, funded by the National Institute for Health and Care Research (NIHR) and CCLG was published. The aim of this study was to help researchers understand the journey that children and young people experience from the start of their symptoms until they receive their cancer diagnosis. The study found that the total time to diagnosis from first symptom to confirmed diagnosis varied widely from the same day to several years. The median time to diagnosis was 4.6 weeks, but this varied by age and cancer type. Teenagers (15-18 years) experienced the longest median time to diagnosis (8.7 weeks), whereas infants under one year had the shortest (3.7 weeks). Among cancer types, bone tumours had the longest median diagnostic interval (12.6 weeks), while kidney tumours had the shortest (2.3 weeks).
- The study findings will help focus efforts towards closing the gap for different groups, ensuring more children and young people receive a diagnosis sooner, and will feed into the Child Cancer Smart campaign, led by CCLG.
- Dr Shaarna Shanmugavadivel, the CCLG-funded Child Cancer Smart fellow, was appointed as the Vice-Chair of the Children and Young People's Cancer Taskforce at the Department of Health and Social Care, ensuring that our research feeds directly into recommendations around better diagnosis for children and young people in the upcoming National Cancer Plan.
- In August, we launched Child Cancer Smart, a national campaign using research findings to develop evidence-based guidelines for primary healthcare professionals, such as GPs, and advice for the general public, with the aim of improving and speeding up diagnosis. The campaign launched with key messages for doctors and other healthcare professionals, alongside resources describing the symptoms of children's cancer. As well as a campaign directed at healthcare professionals, we launched a public awareness campaign with clear messaging, telling parents and the public: "If it doesn't feel right after two weeks, trust your instincts – see a doctor."
- In October, we launched the first suite of Child Cancer Smart tools for professionals, focussed on helping diagnose bone cancer faster. Our resources include updated referral guidelines to help GPs recognise symptoms and know when to act, a decision support tool to guide faster, more confident clinical decisions, and a comprehensive list of the most common bone cancer symptoms. We plan to launch companion sets of resources that will eventually cover all types of cancer commonly seen in children and young people.
- We played a leading role in running the third Teenage and Young Adult Cancer Awareness Month in April. This collaboration is an opportunity for charities and the young people we support to come together and raise awareness of the unique challenges facing this age group.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2025:

- We provided more than 21,000 free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised, with 110 different resources now available from CCLG.
- We produced four issues of our popular magazine, Contact. Feedback continues to be overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- We continued our series of online 'research talks' aimed at parents of children with cancer (and the general public), which aim to explore the world of childhood cancer research in an accessible way, with each episode in the series featuring a talk from an expert speaker, as well as the opportunity for attendees to ask questions. Recordings of the webinars are made available on our YouTube channel for those unable to attend the live events.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching almost 1800 members.
- We successfully passed our annual reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This quality standard is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the children and young people's cancer community. Our Research Strategy outlines our plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure.

In total, between our own research funding and that of the partners we work with, 29 new research projects totalling around £3.8 million were funded in 2025. Grants awarded cover a wide range of cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research.

In 2025:

- We set out to transform children and young people's cancer research with the launch of 'A brighter future: our vision for children and young people's cancer research', our new research strategy. For the first time, our strategy encompassed cancers affecting teenagers and young adults, and spanned the full spectrum of our research activities, from funding ground-breaking projects to leading and influencing the future of cancer research. The strategy is intended to inspire and support the growth of the children and young people's cancer research field, bringing together funders, researchers, patients, survivors and families.
- At the heart of the progressive strategy are four key ambitions. We aim to:
  1. Develop a co-ordinated, collaborative approach to children and young people's cancer research
  2. Fund the best research, led by the brightest minds
  3. Put lived experience at the heart of children and young people's cancer research
  4. Support a thriving children and young people's cancer research community.
- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG over £3 million to fund 16 innovative new research proposals.
- We worked with three other leading cancer charities to develop funding partnerships, resulting in CCLG co-funding 11 ground-breaking research projects. Co-funding with other charities helps us to make our available research funding 'go further', ultimately funding more research, more quickly, than we would be able to do alone.
- We announced a joint research funding call with the Bone Cancer Research Trust, to co-fund a number of research projects into primary bone cancers. This collaboration will allow us to make a significantly larger investment than either organisation would be able to do in isolation, leading to a bigger impact for those diagnosed with bone cancers.
  - With The Bone Cancer Research Trust, we were able to support two new projects into osteosarcoma, and we announced a record £800,000 investment into Ewing sarcoma across four projects, with additional funding support from Great Ormond Street Hospital Charity.
  - With Blood Cancer UK, we co-funded two research projects into childhood leukaemias.
  - With Children with Cancer UK, we co-funded three research projects, covering brain tumours, rhabdomyosarcoma, and childhood leukaemia.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer.

Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 110 Special Named Funds at CCLG (2024: 104), each raising funds to support research into a specific type of childhood cancer.

We continued to develop our internal fundraising strategy, which aims to ensure we are able to sustain our income growth and continue to deliver on our charitable objectives: funding research, supporting families and ensuring that all young patients receive the best possible treatment and care. The strategy includes investment in fundraising to develop our activity in key areas, as well as building on previous investments in data infrastructure which will allow us to make more strategic, data-driven decisions around fundraising activity.

We are hugely grateful to all those who chose to support CCLG, by making a donation, taking part in an event, or organising their own fundraiser during the year.

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into children and young people's cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can also sign up to make regular donations. We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies. CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2025 fall into roughly the same categories as in previous years.

Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £570,640, compared with the year ending December 2024. The majority of this is comprised of an increased in fundraising income from donations and legacies, and an increase in research funding through our partnership with The Little Princess Trust.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2025 by £678,666 compared to 2024. This mainly reflects an increase in research expenditure, some of which was funded through restricted reserves, the increased cost of holding events (reflecting increases in costs in the event industry, including in staffing), particularly our Annual Conference which is now a major event requiring a large venue, and through increased staffing costs.

We ended the year with an overall deficit of £601,378. There was a deficit of unrestricted income and expenditure of £172,822, compared with a deficit of £428,556 in restricted income and expenditure. This reflects our previous commitment to increasing our investment in research, and the fact that much of our restricted income is restricted to research into specific types of cancer, building over several years until there are sufficient funds available to invest in high-quality, impactful research projects.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic followed by a period of global economic uncertainty and inflationary pressure has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what the external environment, particularly in respect of fundraising and charitable giving, looks like in the medium-term.

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy and aim to hold a target level of free reserves (unrestricted fund less tangible fixed asset) of £250,000, which the Trustees consider to be approximately three months of core expenditure, including staff salaries, accommodation costs and general running costs, based on the 2026 budget.

The Trustees consider it prudent to balance the investment of reserves into charitable activity to meet the needs of our beneficiaries and fulfil the wishes of our donors and supporters. Having a reserves policy based on a range rather than a fixed figure, as previously, gives us the flexibility to be more responsive to appropriate opportunities for charitable investment.

Total reserves at 31 December 2025 were £2,193,822 (2024: £2,795,200) of which £1,939,962 (2024: £2,368,518) are restricted and £253,860 (2024: £426,682) are unrestricted. As at 31 December 2025 the charity's free reserves totalled £212,417 (2024: £399,452) which is slightly below the target set out in the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to balance the investment of reserves into our charitable activity whilst ensuring sufficient funds are available to ensure the charity is a 'going concern' and able to meet its commitments and will work to ensure that free reserves are built back to meet the reserves policy while also investing appropriately in charitable activities. The Trustees continue to keep the reserves policy under review to ensure that CCLG is 'fit for the future'.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Our restricted reserves appear high, at £1,939,962 at the end of 2025. Much of our restricted fundraising income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. Our restricted reserves decreased at the end of 2025 compared with 2024, representing our commitment to increase our investment in research, and we expect to see a further decrease at the end of 2026 as we continue to support a wider range of research projects and explore collaborative opportunities with other funders.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the cost-of-living crisis, no further action has been taken on investments.

Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

Following a review of the risk register and the controls in place, the key risks facing the charity are:

- Loss of key staff: we are currently reviewing succession planning and ensuring all systems, plans and procedures are fully documented.
- The ongoing cost-of-living crisis and our ability to fundraise sufficiently to carry out our core activities: we continue to monitor the external environment and have an internal fundraising strategy focused on diversifying and increasing the sustainability of our income.
- Cybersecurity: we are undertaking a programme of work with our IT providers to review and improve our cybersecurity across all organisational systems.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development and share and guide best practice.

Key planned activity for the next 12 months includes:

- Developing and publishing a new strategy which will guide the activities of CCLG over the coming years.
- Launching a platform for people with lived experience of children and young people's cancer to get involved in our work, as well as in research, service development and policy activity across the children and young people's cancer community.
- Launching further suites of disease-specific diagnosis resources as part of our ongoing Child Cancer Smart project, raising awareness of the signs and symptoms in children and young people's cancer and equipping healthcare professionals to make quicker diagnoses.
- We will increase our policy, advocacy and public affairs activity, working in collaboration with other organisations as needed, to ensure that our considerable expertise is used to influence decision-makers and other key stakeholders, inform governments, the NHS and other key organisations, and ultimately contributes to improvements for children and young people with cancer.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

- We will continue to focus on building productive collaborations with other charities where we can share insights, work collectively, co-fund research projects, and otherwise have a bigger impact than we would be able to do working in isolation.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution, and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948). In 2025, CCLG began operating as CCLG: The Children & Young People's Cancer Association.

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for ensuring the charity meets its objectives, delivers on its strategy, has oversight of all activities of the charity, and managing the charity. There are a minimum of two and a maximum of twelve trustees.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

During the year we undertook an open recruitment exercise to increase the number of Trustees, seeking to expand the range of views, professional backgrounds and skills of those on the Board.

The trustees come from a range of professional backgrounds and bring new skills and highly relevant experience. Trustees serving during the year were:
David Oxnam (Chair of Board of Trustees)
Rachel Wilcox (resigned 28 April 2026)
Sarah Curtis
Angela Polanco (appointed 13 June 2025)
Laura Thomas (appointed 28 April 2026)
Angela Ercia (appointed 11 September 2025)
Catherine Anderson (appointed 11 September 2025)
Bushra Khawaja (appointed 11 September 2025)
Natalie Agboeze (appointed 11 September 2025)
Andy Donnelly (appointed 11 September 2025)
Ngozi Ayanru (appointed 11 September 2025)
Hollie Shears (appointed 11 September 2025)

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:
Ashley Ball-Gamble (Chief Executive)
Claire Shinfield (Director of Engagement)
Vicki Brunt (Head of Fundraising)
Sarah Evans (Head of Research)
Phil Welsh (Head of Communications)
Jeanette Hawkins (Chief Nurse)
Jo Stark (Chief Nurse)

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charity's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

DocuSigned by:
David Oxnam
29D0B5FD6D7043C...

David Oxnam
Chair of the board of trustees

Date: 17-09-2026

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2025 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

- performing audit work over revenue recognition including analytical procedures and substantive tests of detail of a sample of revenue transactions; and
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP
Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

17 September 2026

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2025

	Notes	Unrestricted funds 2025 £	Restricted funds 2025 £	Total 2025 £	Total 2024 £
Income from:					
Donations and legacies	**3**	1,029,852	653,622	1,683,474	1,581,702
Charitable activities	**4**	573,310	3,185,467	3,758,777	3,272,798
Investments	**5**	52,820	-	52,820	69,931
Total		1,655,982	3,839,089	5,495,071	4,924,431
Expenditure on:					
Raising funds	**6**	491,211	6,730	497,941	394,603
Charitable activities	**7**	1,337,593	4,260,915	5,598,508	5,023,180
Total		1,828,804	4,267,645	6,096,449	5,417,783
Net expenditure for the year/ Net movement in funds		(172,822)	(428,556)	(601,378)	(493,352)
Reconciliation of funds					
Total funds brought forward		426,682	2,368,518	2,795,200	3,288,552
Total funds carried forward		253,860	1,939,962	2,193,822	2,795,200

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

BALANCE SHEET

AS AT 31 DECEMBER 2025

	Notes	2025 £	2025 £	2024 £	2024 £
Fixed assets					
Tangible assets	**14**		41,443		27,230
Current assets					
Stocks	**15**	37,508		46,019	
Debtors	**16**	3,279,726		3,387,399	
Cash at bank and in hand		2,861,722		4,480,787	
		6,178,956		7,914,205	
Liabilities					
Creditors: amounts falling due within one year	**17**	(2,991,753)		(3,704,081)	
Net current assets			3,187,203		4,210,124
Total assets less current liabilities			3,228,646		4,237,354
Creditors: amounts falling due after more than one year	**18**		(1,034,824)		(1,442,154)
Total net assets			2,193,822		2,795,200
The funds of the charity					
Restricted funds	**20**		1,939,962		2,368,518
Unrestricted funds	**21**		253,860		426,682
Total charity funds			2,193,822		2,795,200

The financial statements were approved and authorised for issue by the board of trustees on 17-09-2026 and are signed on its behalf by:

DocuSigned by:
David Oxnam
29D0B5FD6D7043C...

David Oxnam (Chair of the Board of Trustees)
Trustee

The notes on pages 19 - 33 form part of these financial statements.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	2025		2024	
		£	£	£	£
Cash flows from operating activities					
Cash absorbed by operations	**26**		(1,645,138)		(689,399)
Investing activities					
Purchase of tangible fixed assets		(26,747)		(5,454)	
Investment income received		52,820		69,931	
Net cash generated from investing activities			26,073		64,477
Net cash used in financing activities			-		-
Net decrease in cash and cash equivalents			(1,619,065)		(624,922)
Cash and cash equivalents at beginning of year			4,480,787		5,105,709
Cash and cash equivalents at end of year			2,861,722		4,480,787

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

1 Accounting policies

Charity information
The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation
The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern
At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds
Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition
Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

1 Accounting policies **(Continued)**

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures	5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

1 Accounting policies **(Continued)**

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

3 Income from donations and legacies

	Unrestricted funds 2025	**Restricted funds 2025**	**Total 2025**	Unrestricted funds 2024	Restricted funds 2024	Total 2024
	£	**£**	**£**	£	£	£
Donations	638,498	653,622	1,292,120	626,417	627,879	1,254,296
Legacies	391,354	-	391,354	327,406	-	327,406
	1,029,852	653,622	1,683,474	953,823	627,879	1,581,702

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

4 Income from charitable activities

	Unrestricted funds 2025 £	**Restricted funds 2025 £**	**Total 2025 £**	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Registration fees for meetings and other project expenditure	266,100	3,597	269,697	238,380	11,750	250,130
Member subscriptions and publication payments	188,039	-	188,039	152,428	-	152,428
Grant income for research and operations	119,171	3,101,014	3,220,185	72,803	2,701,486	2,774,289
CLIC Sargent chief nurse funding	-	80,856	80,856	-	95,951	95,951
	573,310	3,185,467	3,758,777	463,611	2,809,187	3,272,798

5 Income from investments

	Unrestricted funds 2025 £	**Total 2025 £**	Unrestricted funds 2024 £	Total 2024 £
Interest	52,820	52,820	69,931	69,931

6 Expenditure on raising funds

	Unrestricted funds 2025 £	**Restricted funds 2025 £**	**Total 2025 £**	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
Costs of raising funds						
Fundraising platform fees	27,643	-	27,643	26,222	-	26,222
Website	2,644	6,730	9,374	2,293	14,934	17,227
Fundraising, marketing and publicity costs	260,481	-	260,481	138,031	36,778	174,809
Support costs (note 10)	200,443	-	200,443	176,345	-	176,345
	491,211	6,730	497,941	342,891	51,712	394,603

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

7 Expenditure on charitable activities

	Activities undertaken directly	Grant funding	Support Costs	Total 2025	Total 2024
	Note 8	Note 9	Note 10		
	£	£	£	£	£
Support for research	292,347	3,897,659	207,495	4,397,501	3,967,943
Information for patients and families	59,307	-	309,790	369,097	342,090
Improving treatment and care	505,943	-	325,967	831,910	713,147
	857,597	3,897,659	843,252	5,598,508	5,023,180
Unrestricted funds				1,337,593	1,103,627
Restricted funds				4,260,915	3,919,553
				5,598,508	5,023,180

8 Expenditure on activities undertaken directly

	Support for research	Information for patients and families	Improving treatment and care	Total 2025	Total 2024
	£	£	£	£	£
Staff costs	217,604	-	-	217,604	205,335
Other tumour specific expenditure	65,369	-	-	65,369	156,255
Contact magazine expenses	-	24,249	-	24,249	20,306
Other publication expenses	-	20,996	-	20,996	20,446
Website	9,374	14,062	14,063	37,499	68,912
Cost of meetings	-	-	443,841	443,841	344,837
Travel expenses	-	-	16,359	16,359	16,893
Membership support costs	-	-	24,462	24,462	24,094
Other expenses	-	-	7,218	7,218	6,540
	292,347	59,307	505,943	857,597	863,618

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

9 Expenditure on grant funding

	Support for research £	Total 2025 £	Total 2024 £
Grants to institutions:			
University of Birmingham	184,854	184,854	350,207
University of Surrey	287,410	287,410	112,216
Newcastle University	547,097	547,097	(474)
UCL Institute of Child Health	838,513	838,513	345,890
University of Nottingham	351,130	351,130	81,543
University of Bristol	55,715	55,715	61,069
Great Ormond Street	19,700	19,700	702,390
University of Southampton	158,482	158,482	-
University Hospital of Wales	-	-	(33,114)
University of Glasgow	100,000	100,000	216,831
University of York	191	191	252,682
University of Cambridge	375,205	375,205	493,268
Institute of Cancer Research	197,661	197,661	186,225
University of Leeds	32,608	32,608	61,556
University of Manchester	53,892	53,892	-
University of Oxford	60,000	60,000	99,701
University College Cork	(438)	(438)	4,950
Swansea University	-	-	230,943
Birmingham Children's Hospital	79,888	79,888	-
King's College London	-	-	74,458
The Open University	22,104	22,104	(94)
University of Edinburgh	100,000	100,000	-
Imperial College London	73,299	73,299	-
Sheffield Children`s Foundation Trust	-	-	19,949
University Hospitals Bristol and Weston NHS Trust	-	-	19,743
University of East Anglia	-	-	124,360
University College Dublin	237,806	237,806	-
University of Strathclyde	22,780	22,780	-
Alder Hey Children's Hospital NHS Foundation Trust	93,475	93,475	-
Institut de Recerca Sant Joan de Déu	6,287	6,287	-
	3,897,659	3,897,659	3,404,299

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made, returned to CCLG.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

10 Expenditure on support costs

	Basis of allocation	2025	2024
		£	£
Staff costs	*1	824,901	716,066
Depreciation & loss on disposal	*1	12,534	9,228
Occupancy expenses	*1	141,412	131,991
Postage	*1	15,993	15,896
Staff training	*1	7,374	8,571
Professional fees	*1 / *2	41,481	49,856
		1,043,695	931,608
Analysed between			
Raising funds		200,443	176,345
Charitable activities		843,252	755,263
		1,043,695	931,608

*1 Support costs, excluding governance costs, have been allocated as follows:

Cost of raising funds	20% (2024 - 20%)
Charitable activities	
Support for research	20% (2024 - 20%)
Information for patients and families	30% (2024 - 30%)
Improving treatment and care	30% (2024 - 30%)

*2 Professional fees include governance costs of £41,481 (2024 - £49,856). Governance costs have been allocated as follows:

Charitable activities	
Support for research	17% (2024 - 17%)
Information for patients and families	22% (2024 - 22%)
Improving treatment and care	61% (2024 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:
- statutory audit £10,764 (2024 - £10,140)
- other services £1,639 (2024 - £1,382)

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Trustees

Except for the disclosures below, none of the trustees received any remuneration, benefits or reimbursements from the charity during the year, or in the previous year.

During the year, expenses were reimbursed to the following trustees:
N Agboeze was reimbursed £104 (2024 - £Nil) for meeting expenses;
H Shears was reimbursed £104 (2024 - £Nil) for meeting expenses;
A Donnelly was reimbursed £130 (2024 - £Nil) for meeting expenses.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

13 Employees

The average monthly number of employees during the year was:

	2025 Number	2024 Number
Total	26	24

Employment costs	2025 £	2024 £
Wages and salaries	850,097	769,767
Social security costs	104,114	75,889
Other pension costs	88,294	75,745
	1,042,505	921,401

The number of employees whose annual remuneration (excluding pension contributions) was more than £60,000 is as follows:

	2025 Number	2024 Number
£60,001 - £70,000	-	1
£70,001 - £80,000	1	-
£100,001 - £110,000	-	1
£110,001 - £120,000	1	-

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

	2025 £	2024 £
Aggregate compensation	418,207	377,924

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

14 Tangible fixed assets

	Computer equipment, furniture and fixtures	Total
	£	£
Cost		
At 1 January 2025	95,484	95,484
Additions	26,747	26,747
Disposals	(21,239)	(21,239)
At 31 December 2025	100,992	100,992
Depreciation and impairment		
At 1 January 2025	68,254	68,254
Depreciation charged in the year	12,534	12,534
Eliminated in respect of disposals	(21,239)	(21,239)
At 31 December 2025	59,549	59,549
Carrying amount		
At 31 December 2025	41,443	41,443
At 31 December 2024	27,230	27,230

15 Stocks

	2025	2024
	£	£
Merchandise stock	16,443	23,412
Educational literature	21,065	22,607
	37,508	46,019

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

16 Debtors

Amounts falling due within one year:	2025 £	2024 £
Trade debtors	40,243	25,298
Grant debtors	1,959,926	2,239,464
Rent deposit	18,600	18,600
Prepayments and accrued income	322,048	238,554
Accrued legacy income	248,000	283,500
	2,588,817	2,805,416

Amounts falling due after more than one year:	2025 £	2024 £
Grant debtors	690,909	581,983
Total debtors	3,279,726	3,387,399

17 Creditors: amounts falling due within one year

	2025 £	2024 £
Deferred income	51,599	32,241
Trade creditors	101,292	8,729
Grant creditors	2,794,724	3,622,339
Accruals	44,138	40,772
	2,991,753	3,704,081

Deferred income includes income received in respect of meetings to be held in the next financial year.

18 Creditors: amounts falling due after more than one year

	2025 £	2024 £
Grant creditors	1,034,824	1,442,154

19 Retirement benefit schemes

Defined contribution schemes
The charity operates a defined contribution pension scheme for all qualifying employees.

The amount of contribution recognised in unrestricted expenditure was £88,294 (2024 - £75,745).

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

		Movement in funds			
	Balance at 1 January 2025	Income	Expenditure	Transfers	Balance at 31 December 2025
	£	£	£	£	£
Tumour specific funds	1,538,874	652,532	(775,921)	-	1,415,485
CCLG Prize	364	-	-	-	364
General research fund	15,920	-	-	-	15,920
Adam Hay fund	11,262	-	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	2,100	984	-	-	3,084
The Little Princess Trust fund	6,200	3,101,014	(3,101,014)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	2,040	-	-	-	2,040
Child Cancer Smart	35,190	-	-	-	35,190
PORT	420	-	-	-	420
CCLG Research Network Partner Charity	15,000	-	-	-	15,000
Neuroblastoma Nursing Group	1,500	-	-	-	1,500
PODC - Iraq Fund	7,891	3,203	(42)	-	11,052
Young Lives vs Cancer Chief Nurse Funding	589	80,856	(84,252)	2,807	-
Health Information	16,920	-	-	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,496	-	-	-	66,496
Projects Restricted Fund	646,131	500	(306,416)	(2,807)	337,408
	2,368,518	3,839,089	(4,267,645)	-	1,939,962

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

20 Restricted funds **(Continued)**

	Balance at 1 January 2024	Movement in funds: Income	Expenditure	Transfers	Balance at 31 December 2024
	£	£	£	£	£
Tumour specific funds	1,605,293	1,006,365	(1,072,784)	-	1,538,874
CCLG Prize	364	-	-	-	364
General research fund	5,670	10,250	-	-	15,920
Adam Hay fund	11,262	-	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	6,850	915	(5,665)	-	2,100
POTG	2,156	10,170	(16,449)	4,123	-
The Little Princess Trust fund	6,200	2,314,140	(2,314,140)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	21,632	-	(19,592)	-	2,040
Child Cancer Smart	37,786	-	(2,596)	-	35,190
PORT	420	-	-	-	420
CCLG Research Network Partner Charity	-	15,000	-	-	15,000
Neuroblastoma Nursing Group	1,500	-	-	-	1,500
PODC - Iraq Fund	9,694	850	(2,653)	-	7,891
Young Lives vs Cancer Chief Nurse Funding	2,332	79,376	(81,119)	-	589
Health Information	16,920	-	-	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,496	-	-	-	66,496
Projects Restricted Fund	1,102,398	-	(456,267)	-	646,131
	2,898,594	3,437,066	(3,971,265)	4,123	2,368,518

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds
Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize
Represents income received from donors to fund the CCLG Prize.

General research fund
Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund
This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group
Represents income received from the Senior Members' Group to be used for their activities.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

20 Restricted funds **(Continued)**

PODC
Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG
Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund
Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund
Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter
Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart
Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT
Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charities
Represents income received from other charities to fund and support research projects.

Neuroblastoma Nursing Group
Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

PODC - Iraq Fund
Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Young Lives vs Cancer Chief Nurse Funding
Funding for the Chief Nurse role and associated projects. Funds were transferred from our Projects Restricted Funds to the Young Lives vs Cancer Chief Nurse Funding to underwrite a cash deficit on the fund. The related expenditure is in line with the restricted purpose of the Projects Restricted Funds.

Health Information
Funds received to support the production of health information for patients and families.

TYAC General Restricted
Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research
Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds
Income restricted to support specific projects including work related to research. Funds were transferred from our Projects Restricted Funds to the Young Lives vs Cancer Chief Nurse Funding to underwrite a cash deficit on the fund. The related expenditure is in line with the restricted purpose of the Projects Restricted Funds.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

21 Unrestricted funds

	Balance at 1 January 2025	Movement in funds: Income	Expenditure	Transfers	Balance at 31 December 2025
	£	£	£	£	£
General funds	426,682	1,655,982	(1,828,804)	-	253,860

	Balance at 1 January 2024	Movement in funds: Income	Expenditure	Transfers	Balance at 31 December 2024
	£	£	£	£	£
General funds	389,958	1,487,365	(1,446,518)	(4,123)	426,682

22 Analysis of net assets between funds

	Unrestricted funds 2025	Restricted funds 2025	Total 2025
	£	£	£
Fund balances at 31 December 2025 are represented by:			
Tangible assets	41,443	-	41,443
Current assets/(liabilities)	212,417	2,974,786	3,187,203
Long term liabilities	-	(1,034,824)	(1,034,824)
	253,860	1,939,962	2,193,822

	Unrestricted funds 2024	Restricted funds 2024	Total 2024
	£	£	£
Fund balances at 31 December 2024 are represented by:			
Tangible assets	27,230	-	27,230
Current assets/(liabilities)	399,452	3,810,672	4,210,124
Long term liabilities	-	(1,442,154)	(1,442,154)
	426,682	2,368,518	2,795,200

23 Events after the reporting date

The charity was notified of an additional legacy during a prior year. The timing and amount of the legacy income is uncertain as at the balance sheet date and therefore no income relating to this legacy has been recognised in these accounts.

Docusign Envelope ID: B3F3B34E-4C38-89DA-8371-D3ED53534A11

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2025 £	2024 £
Within one year	39,096	39,096
Between two and five years	98,214	137,310
	137,310	176,406

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £39,096 (2024 - £37,471).

25 Related party transactions

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

26 Cash generated from operations	2025 £	2024 £
Deficit for the year	(601,378)	(493,352)
Adjustments for:		
Investment income recognised in statement of financial activities	(52,820)	(69,931)
Depreciation and impairment of tangible fixed assets	12,534	9,228
Movements in working capital:		
Decrease in stocks	8,511	9,042
Decrease in debtors	107,673	1,986,481
(Decrease) in creditors	(1,139,016)	(2,143,549)
Increase in deferred income	19,358	12,682
Cash absorbed by operations	(1,645,138)	(689,399)

27 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.